Ruxolitinib ointment launch date in China

Ruxolitinib ointment (Opzelura ) is an innovative topical drug mainly used to treat skin diseases caused by immune system abnormalities, especially vitiligo and mild to moderate atopic dermatitis (eczema). Ruxolitinib is a potent JAK inhibitor that blocks the activity of JAK enzyme and reduces the release of pro-inflammatory factors, thereby effectively relieving skin redness, itching and inflammatory reactions. Compared with traditional treatment methods, ruxolitinib ointment has more significant efficacy, relatively fewer side effects, and higher patient compliance.

Currently, ruxolitinib ointment is not yet available in China, so domestic patients cannot obtain the drug through local pharmacies or hospitals. This forces many patients in need to purchase through overseas channels. According to market conditions, the price of foreign original drugs is quite high, and you usually need to pay more than 10,000 yuan. This constitutes a considerable burden for patients with limited financial conditions. However, generic drugs produced in Bangladesh are attracting attention as a more economical alternative. The price of this generic drug is relatively low, about a few hundred yuan, and its ingredients and efficacy are basically the same as the original drug, making it the first choice for many patients.

For Chinese patients, the introduction of ruxolitinib ointment is expected to be realized in the future. With the continuous opening of the Chinese drug market and the acceleration of the drug approval process, the drug may enter the Chinese market and be widely used in the next few years. Prior to this, when patients choose to purchase and use overseas drugs, they should ensure that they are purchased through formal and reliable channels and used rationally under the guidance of professional medical personnel to ensure drug safety and therapeutic effects.